<i>MLH1</i> promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas
Enami Kaneko, Naoki Sato, Tae Sugawara, Aya Noto, K Takahashi, Kenichi Makino, Yukihiro Terada
Abstract
OBJECTIVE: -PHM. METHODS: -PHM as "suspected-LS." The clinical features, including long-term prognosis, of each group, were analyzed. RESULTS: Accordingly, 419 (79.5%), 65 (12.3%), and 43 (8.2%) cases were categorized as "MMR-proficient," "suspected-LS," and "met-EC," respectively. Significantly, "met-EC" had a lower proportion of grade 1 tumors (37.5%) and a higher proportion of stage III/IV tumors (37.2%) than the other groups. The overall and progression-free survival of "met-EC" were significantly worse than those of "suspected-LS" in all cases. CONCLUSION: In ECs with MMR-D, "met-ECs" were a subgroup with a poorer prognosis than "suspected-LS." "Met-ECs" would be the main target for anti-PD-1 antibody treatment, and its clinical susceptibility should be verified individually.